NCT07784270ClinicalTrials.gov
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
En bref
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Phase 31 500 participants recherchés230 sites16 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT07784270Ouvrir cette fiche sur ClinicalTrials.govSynchronisé il y a 3 semaines
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 5 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-20
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 218 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 1,500 participants (target), run at 230 sites, across 16 countries.
How this score is built
- Enrolment32/40
1,500 participants (target)
- Site count25/25
218 sites
- Country count15/15
16 countries
- Planned duration7/10
Planned over about 24 months
- Sponsor scale10/10
AstraZeneca has led 1,017 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Affections
- Obesity or Overweight
- Diabetes Mellitus, Type 2
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 18 Years – Aucun maximum |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 3 |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | QUADRUPLE (4) |
| Recrutement | 1 500 participants recherchés |
Promoteur et collaborateurs
- AstraZeneca Promoteur
Groupes et interventions
- AZD6234 Dose 1EXPERIMENTAL
AZD6234 Dose 1
- AZD6234 Dose 2EXPERIMENTAL
AZD6234 Dose 2
- PlaceboPLACEBO_COMPARATOR
Matching placebo
Interventions
- Médicament Lenbelintide
IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
- Médicament Placebo
Placebo matching IMP dose injected subcutaneously, once a week.
Critères de jugement
Critère de jugement principal
Percent change in body weight from baseline at 68 weeks of treatment.
To evaluate the effect of AZD6234 compared to placebo in percent body weight change
Délai 68 weeks
Critère de jugement secondaire
Absolute change in weight (kg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on absolute change in weight
Délai 68 weeks
Critère de jugement secondaire
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%
Délai 68 weeks
Critère de jugement secondaire
Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%
Délai 68 weeks
Critère de jugement secondaire
Change in haemoglobin A1C from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 on haemoglobin A1C change
Délai 68 weeks
Critère de jugement secondaire
Change in waist circumference (cm) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on waist circumference change
Délai 68 weeks
Critère de jugement secondaire
Percent change in triglycerides from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change
Délai 68 weeks
Critère de jugement secondaire
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change
Délai 68 weeks
Critère de jugement secondaire
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants
Délai 68 weeks
Dates
| Date de début | 20 août 2026 (réelle) |
|---|---|
| Achèvement principal | 9 août 2028 (estimée) |
| Achèvement | 9 août 2028 (estimée) |
| Première publication | 25 août 2026 (réelle) |
| Dernière mise à jour | 28 octobre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | octobre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
58 sites sont en recrutement
Argentina
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | Buenos Aires | En recrutement | |
| Research Site | CABA | En recrutement | |
| Research Site | Ciudad de Buenos Aires | En recrutement | |
| Research Site | Mendoza | En recrutement | |
| Research Site | Ramos Mejía | Pas encore en recrutement | |
| Research Site | Rosario | En recrutement | |
| Research Site | San Nicolás | Pas encore en recrutement |
Australia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | Botany | En recrutement | |
| Research Site | Camberwell | En recrutement | |
| Research Site | Charlestown | En recrutement | |
| Research Site | Helensvale | En recrutement | |
| Research Site | Maroubra | En recrutement | |
| Research Site | Waitara | En recrutement |
Canada
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | Calgary | Alberta | En recrutement |
| Research Site | Hamilton | Ontario | En recrutement |
| Research Site | Joliette | Quebec | En recrutement |
| Research Site | Markham | Ontario | En recrutement |
| Research Site | Moncton | New Brunswick | En recrutement |
| Research Site | Montreal | Quebec | En recrutement |
| Research Site | Montreal | Quebec | En recrutement |
| Research Site | North York | Ontario | En recrutement |
| Research Site | Québec | Quebec | En recrutement |
| Research Site | Sarnia | Ontario | En recrutement |
| Research Site | Scarborough Village | Ontario | En recrutement |
| Research Site | Stoney Creek | Ontario | Retiré |
| Research Site | Stouffville | Ontario | En recrutement |
| Research Site | Toronto | Ontario | En recrutement |
| Research Site | Toronto | Ontario | En recrutement |
| Research Site | Trois-Rivières | Quebec | En recrutement |
| Research Site | Truro | Nova Scotia | En recrutement |
| Research Site | Vancouver | British Columbia | En recrutement |
Chile
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | Concepción | Pas encore en recrutement | |
| Research Site | Concepción | Pas encore en recrutement | |
| Research Site | Concepción | Pas encore en recrutement | |
| Research Site | Iquique | Pas encore en recrutement | |
| Research Site | Las Condes | Pas encore en recrutement | |
| Research Site | Providencia | Pas encore en recrutement | |
| Research Site | Santiago | Pas encore en recrutement | |
| Research Site | Santiago | Pas encore en recrutement | |
| Research Site | Santiago | Pas encore en recrutement |
China
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Research Site | Beijing | Pas encore en recrutement | |
| Research Site | Cangzhou | Pas encore en recrutement | |
| Research Site | Changchun | Pas encore en recrutement | |
| Research Site | Chengdu | Pas encore en recrutement | |
| Research Site | Chengdu | Pas encore en recrutement | |
| Research Site | Danyang | Pas encore en recrutement | |
| Research Site | Ganzhou | Pas encore en recrutement | |
| Research Site | Guangzhou | Pas encore en recrutement | |
| Research Site | Huizhou | Pas encore en recrutement | |
| Research Site | Huzhou | Pas encore en recrutement |
180 sites supplémentaires sont indiqués dans la fiche du registre.
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 28 octobre 2026
Date d'achèvement reportée
Primary completion delayed 1 days
2028-08-082028-08-09
- 28 octobre 2026
Site ajouté
3 sites added (230 total)
227230
- 22 septembre 2026
Statut modifié
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 22 septembre 2026
Recrutement ouvert
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 22 septembre 2026
Date d'achèvement avancée
Primary completion advanced 1 days
2028-08-092028-08-08
- 22 septembre 2026
Site ajouté
9 sites added (227 total)
218227